The challenge of a late diagnosis of Autism Spectrum Disorder: co-occurring trajectories and camouflage tendencies. a case report of a young Autistic female with Avoidant Restrictive Food Intake Disorder Authors: Sara Passarini, Silvia Guerrera, Maria Picilli, Elisa Fucà, Laura Casula, Deny Menghini, Sabine Pirchio, Valeria Zanna, Giovanni Valeri, Stefano Vicari Published: 2025 ABSTRACT IntroductionAutistic individuals may show several psychiatric co-occurrences, including Feeding and Eating Disorders (FEDs). Avoidant and Restrictive Food Intake Disorder (ARFID) consists of avoidance or restriction in food intake, leading to significant weight loss, nutritional deficiencies, and marked interference with psychosocial functioning. Both Autism Spectrum Disorder (ASD) and ARFID are characterized by the two main features of cognitive rigidity and sensory sensitivity, which may complicate differential diagnosis. There is a notable lack of information on the manifestation of ASD-ARFID co-occurrence, as well as tailored assessment tools and practice, and therapeutic approaches.Case descriptionThis report provides a detailed description of L., a young girl with a late diagnosis of ASD who also developed unspecific depressive mood disorder and ARFID in co-occurrence. After the diagnosis of ASD, L. underwent multiple evaluations to address emerging psychiatric co-occurrences and symptom exacerbation, and in order to develop the most effective integrated treatment.ConclusionThe case of L. expands the knowledge on the phenotype of Autistic females and exemplifies how delayed diagnosis may exacerbate functioning differences and increase the camouflage phenomenon. Additionally, it underscores the importance of improving tailored evaluation, combined treatment plans, with both cognitive-behavioral therapy and drugs, and monitoring the evolving patterns of Autistic manifestations and associated psychiatric co-occurrences. Introduction Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by the early onset of neurodivergent characteristics in social communication along with restricted interests and repetitive behaviors (RRBs) (1, 2); its current global prevalence is estimated at around 1% (3). The diagnosis of ASD is often associated with a high likelihood of developing psychiatric co-occurrences such as anxiety disorders (estimated 30–39%), depressive disorder (estimated 15–21%), schizophrenia spectrum and other psychotic disorders (estimated 7–13%), suicidal ideation and attempts (estimated 1-66%), obsessive-compulsive disorder (estimated 7–10%), disruptive, impulse-control and conduct disorders (estimated 13–22%) and Attention Deficit Hyperactivity Disorder (estimated 28–46%) (4, 5). The prevalence rates of psychiatric co-occurrences in ASD may vary due to sample features (e.g. age), assessment methods, and individual cognitive abilities. Co-occurrences seem to persist from childhood to adolescence and adulthood (6, 7), worsening long-term outcomes, including increased mortality risk (6). The age of Autistic individuals is a crucial for understanding developmental trajectories, with an intensification of psychiatric co-occurrences along the growth (8). Although co-occurring symptoms usually appear early in development, the co-occurring diagnosis is often missed until adolescence (9), due to diagnostic overshadowing (10). For instance, less engagement in social participation is often mistakenly attributed to social anxiety disorder, while specific interests are sometimes confused with obsessive-compulsive disorder (11). However, few studies have explored the characteristics and progression of co-occurring conditions in Autistic individuals (7, 12–14). Additionally, sex may affect co-occurring conditions, with females experiencing higher rates of depression, anxiety, suicidality, and eating disorders (15). For example, depressive symptoms tend to increase during adolescence in Autistic females than in males (7, 16). Another common psychiatric co-occurrence associated with ASD is feeding and eating disorders (FED), with an estimated percentage of 20-46% (4). Currently, FEDs are conceptualized as a heterogeneous group of conditions such as anorexia nervosa, bulimia nervosa, binge eating disorder and avoidant restrictive food intake disorder (ARFID) (2). While anorexia nervosa or bulimia are characterized by obsessions with food, body weight, and shape, along with related thoughts and emotions that cause significant disturbances in a person’s eating behaviors (17), ARFID involves significant disruptions in nutritional and caloric intake that exceed typical variations in hunger, food preferences, or interest in eating (18). Hence, ARFID is more closely associated with disorders like pica and rumination (19–21). Further, differently from anorexia nervosa and bulimia nervosa, ARFID can only be diagnosed in the absence of concerns about body weight or shape. While individuals with anorexia nervosa fear caloric intake, ARFID concerns are often focused on the fear of choking during eating (22, 23). However, both anorexia nervosa and ARFID can present with strict food rules (24, 25), as well as low weight and malnutrition, necessitating a multidisciplinary approach (e.g. physicians, mental health professionals, dietitians, and family members) to restore weight (21). Autistic individuals are more likely to experience eating issues compared to the general population (12, 13). Indeed, a substantial portion of Autistic children, approximately from 44% to 89%, experience feeding challenges (26). Meanwhile, people with FEDs seem to exhibit more Autistic traits (27, 28), with an estimated percentage of 8-37% for anorexia nervosa, and about 12.5% for ARFID (28). ASD and FED co-occurrence may be explained by selective eating, described as a strong preference for specific food (e.g. sweets and calorie-dense food), typically grounded on foods’ color, shape, texture, or temperature (29). Further, Autistic children tend to show sensory differences and rigid patterns of mealtime behaviors, entailing feeding problems with fussy eating, limited food repertoire and amount of food consumed (5, 30). Other potential links between ASD and FEDs may be shared cognitive difficulties concerning underdeveloped theory of mind, emotional difficulties (e.g. empathy and alexithymia), set-shifting and cognitive inflexibility (28). Specifically, ARFID is more commonly co-occurring in Autistic children and adolescents compared to anorexia nervosa or bulimia, due to food selectivity and sensory sensitivity, which are main features of ARFID (31). Focusing on ARFID, the condition involves avoiding foods for specific sensory-related aspects, fear of adverse consequences from feeding, and an overall lack of interest in eating, without any links to body image disturbances and fears of gaining weight (2). ARFID commonly generates adverse physical consequences and hampers the psychosocial functioning of individuals (2, 32, 33). ASD and ARFID may coexist, with an estimated percentage of 20% (34). Of note, ASD and ARFID co-occurrence may be explained by a symptomatology overlap characterized by cognitive rigidity and sensory sensitivity (33). Atypical sensory processing appears to characterize both ASD and ARFID, potentially moderating their interrelation. As a result, sensory inputs would be misinterpreted generating maladaptive behaviors (35) such as children’s overreaction to foods and eating aversion (36). Moreover, the presence of a diagnosis of ASD would enhance possibilities of meeting ARFID criteria, worsening eating difficulties rather than anticipating its onset (30). Studies on ARFID characterization in Autistic children pointed the sensory sensitivity as the most prevalent symptom (30). However, more searches are needed to look into ASD-ARFID co-occurrence focusing their presentation as well as assessment procedures and tools to grab their co-occurrence (30). Based on the available evidence, we describe the case of a Caucasian female adolescent with a late diagnosis of ASD along with mood and feeding co-occurrences, who has been attending our outpatient units since September 2021. Case description Family history L. has a twin brother, with unspecified learning disorders, and a younger brother. There is no known family history of psychiatric disorders; however, L’s parents reported a suspicion of obsessive-compulsive disorder in her maternal grandmother, who did not undergo formal evaluation. Previous patient developmental and clinical history L. is a Caucasian 14-year-old girl undergoing evaluation at the Child and Adolescent Psychiatry Unit of the Bambino Gesù Children’s Hospital, IRCCS due to progressively restricting her food intake, which is co-occurring with a diagnosis of ASD. L. was born to non-related parents through a homologous in vitro fertilization twin pregnancy without complications. The amniocentesis had revealed a normal fetal karyotype. Delivery occurred via planned caesarean section at 36 weeks gestation (birth weight: 2240 grams; Apgar: 8-9). Her perinatal history was regular. Concerning neurodevelopmental history, independent walking emerged at 12 months and first words at 14 months. Later, L. showed a language disorder, specifically in the expressive domain, requiring speech therapy from 4.5 to 8 years. At 4 years, an audiometric examination was conducted displaying no irregularities. Since early childhood, she exhibited social interaction difficulties with peers, restricted interests, and selective eating with restricted range of foods. In February 2020, at 10 years of age, L. underwent a cognitive diagnostic assessment in a private center with the Wechsler Intelligence Scale for Children- fourth edition (37), revealing an average cognitive functioning. A deeper investigation into Autistic traits was suggested as her family reported difficulties in peer relationships, hypersensitivity to noise, and selective eating. Mood fluctuations have been reported for about a year. In August 2020, at 10 years, the investigation on Autistic traits was performed in a private center. L. underwent the Autism Diagnostic Observation Schedule-2 (38) revealing a calibrated severity score of 7/10. Clinicians highlighted the presence of restricted interests in stuffed toys, tendency towards isolation, frustration and irritability. The diagnosis of ASD in co-occurrence with an unspecified depressive disorder was made. Therapeutic prescriptions indicated weekly sessions of individual cognitive-behavioral therapy (CBT) combined with a psycho-educational group aimed at promoting communication strategies to support L. express their experiences, interests, feelings, and thoughts. Since September 2021, she exhibited a worsening of her clinical conditions with inappetence and severe weight loss of approximately 11 kg over nine months (from 58 kg to 47 kg). In June 2022, at 12 years, L. attended the Emergency Unit of Bambino Gesù Children’s Hospital, IRCSS, due to her serious weight loss, with a BMI of 18.8. L. denied purposely restrictive and dietary conduct and compensating behaviors. Her family reported persistent difficulties in relating with peers and mood fluctuations. They also reported frequent sleep irregularities characterized by difficulties in falling asleep. During the examination, clinicians pointed out cognitive rigidity, limited engagement in conversation, laconic speech, monotone tone, and Autistic traits. There were no misperceptions and suicidal ideation. The prescription for a deeper feeding evaluation was suggested. Clinical observation findings Sequentially, L. was referred to the Feeding and Eating Disorders Outpatient Unit of the Child and Adolescent Psychiatry Unit, Bambino Gesù Children’s Hospital, IRCSS for an overall neuropsychiatric assessment. Table 1 provides the detailed assessment protocol. Based on DSM-5 criteria (54), a clinical diagnosis of ARFID was made in co-occurrence with ASD and unspecified depressive disorder. A nutritional plan was designed; prescriptions suggested individual CBT, family psychotherapy and parent training. Table 1Table of neuropsychological and psychopathological evaluations.Neuropsychological and Psychopathological toolsFirst evaluation(June 2022)Second evaluation (September 2022) WISC-IV (37)Total IQ indexNot performed115Average scoreVerbal index108Average scorePerformance index126High Average scoreWorking memory Index103Average score ADOS-2 (38)Social affect domainNot performedCSS= 7/10Restrictive and repetitive behaviors domainCSS= 4/ 10Overall ADOS-2CSS= 6/10 Autism ADI-R (39)Reciprocal social interactionNot performed14/10Cut off= 10Communication10/8Cut off= 8Restrictive and repetitive behaviors1/3Cut off= 3Development2/1Cut off= 1 SRS (40)Total scoreNot performedT-score: >90 Severe Profile Social awarenessT-score: 60Mild scoreSocial cognitionT-score: 74Moderate scoreSocial communicationT-score: >90Severe scoreSocial motivationT-score: >90Severe scoreRestrictive and repetitive behaviorsT-score: 88Severe score ABAS-II (41)Composite index Not performedPercentile: <1st Extremely Low scoreConceptual domainPercentile: <1st Extremely Low scoreSocial domainPercentile: <1st Extremely Low scorePractical domainPercentile: 3rd Extremely Low score CBCL/ 6-18 (42, 43) Competence scale scores ActivitiesT-score: 47Average scoreT-score: 46Average scoreSocialT-score: 32Average scoreT-score: 25Clinical scoreSchoolNot computableNot computableTotal competence scoreNot computableNot computable Syndrome scale scores Anxious/ DepressedT-score: 62Average scoreT-score: 74Clinical scoreWithdrawn/ DepressedT-score: 93Clinical scoreT-score: 100Clinical scoreSomatic ComplaintsT-score: 78Average scoreT-score:70Clinical scoreSocial problemsT-score: 61Average scoreT-score: 68Borderline scoreThought problemsT-score: 69Average scoreT-score: 75Clinical scoreAttention problemsT-score: 63Average scoreT-score: 68Borderline scoreRule-breaking behaviorT-score: 57Average scoreT-score: 64Average scoreAggressive behaviorT-score: 52Average scoreT-score: 67Borderline score Internalizing, Externalizing, Total Problems, and Other Problems Internalizing problemsT-score: 76 Clinical scoreT-score: 78Clinical scoreExternalizing problemsT-score: 54Average scoreT-score: 67Clinical scoreTotal problemsT-score: 67Average scoreT-score: 73Clinical score DSM-Oriented Scales Depressive problemsT-score: 77Clinical scoreT-score: 88Clinical scoreAnxiety problemsT-score: 55Average scoreT-score: 64Average scoreSomatic problemsT-score: 77Clinical scoreT-score: 66Borderline scoreAttention deficitT-score: 52Average scoreT-score: 60Average scoreOppositional defiant problemsT-score: 51Average scoreT-score: 67Borderline scoreConduct problemsT-score: 51Average scoreT-score: 61Average score 2007 Scale scores Sluggish Cognitive TempoT-score: 73 Clinical ScoreAverage scoreT-score: 75Clinical scoreObsessive Compulsive ProblemsT-score: 66Average scoreT-score: 69Borderline scoreStress ProblemsT-score: 67Average scoreT-score: 82Clinical score PSI (44)Total parental distressPercentile: 80th Clinical scorePercentile: 80th Clinical scoreParental DistressPercentile: 90th Clinical scorePercentile: 95th Clinical scoreParent–Child Dysfunctional InteractionPercentile: 95th Clinical scorePercentile: 100th Clinical scoreDifficult ChildPercentile: 95th Clinical scorePercentile: 100th Clinical score ABC (45)Not performedNo clinical scores MASC-2 (self-report) (46)Anxiety probability:1 Borderline anxiety probability Not performedTotal scoreT-score: 50Average scoreSeparation anxiety/ phobiasT-score: 72Clinical scoreSocial anxietyT-score: 44Average scoreGAD indexT-score: 52Average scoreHumiliation/RejectionT-score: 40Average scorePerformance fearsT-score: 53Average scoreObsessions and CompulsionsT-score: 43Average scorePhysical symptomsT-score: 59Average scorePanic T-score: 66Borderline scoreTense/ RestlessT-score: 49Average scoreHarm AvoidanceT-score: 40Average scoreInconsistency index6cut off>10 MASC-2 (parent-report) (46)Anxiety probability:Not performed3 Very Elevated anxiety probability Total scoreT-score: 78Clinical scoreSeparation anxiety/ phobiasT-score: 62Borderline scoreSocial anxietyT-score: 88Clinical scoreGAD indexT-score: 83Clinical scoreHumiliation/RejectionT-score: 83Clinical scorePerformance fearsT-score: 84Clinical scoreObsessions and CompulsionsT-score: 46Average scorePhysical symptomsT-score: 81Clinical scorePanic T-score: 88Clinical scoreTense/ RestlessT-score: 70Clinical scoreHarm AvoidanceT-score: 56Average scoreInconsistency index6cut-off >8 CDI-2 (parent-report) (47)Total scoreNot performedT-score: 66 Elevated overall score: more concerns than are typically reported Emotional problemsT-score: 74Clinical scoreFunctional problemsT-score: 57Average score CDI-2 (self-report) (47)Total scoreT-score: 68 Elevated overall score: more concerns than are typically reported Not performedEmotional problemsT-score: 61High average scoreNegative mood/ Physical symptomsT-score: 64High average scoreNegative self-esteemT-score: 55Average scoreFunctional problemsT-score: 72Clinical scoreInterpersonal problemsT-score: 57High average scoreIneffectivenessT-score: 70Clinical score SDSC (48)Disorders in initiating and maintaining sleepNot performedT-score: 60Average scoreSleep breathing disordersT-score: 45Average scoreDisorders of arousal nightmaresT-score: 47Average scoreSleep wake transition disordersT-score: 46Average scoreDisorders of excessive somnolenceT-score: 77Clinical scoreSleep hyperhidrosisT-score: 45Average scoreTotal SDSC scoreT-score: 58Average score SSP-2 (49)Not performedThe sensory processing pattern categorized into “like others” YSR (43)Non scorable, incomplete compilationNot performed BUT (50)Non scorable, incomplete compilationNot performed EDI- 3 (51)Non scorable, incomplete compilationNot performed K-SADS-PL (self and parent report) (52)-Diminished appetite and reduced interest in food, with avoidance of certain foods and occasional meal skipping. Neither body dysmorphia nor fear of gaining weight (from 11 years old). -Anhedonia, apathy, emotional instability, irritability, fatigue, difficulty concentrating, a lack of response to positive stimuli, and a propensity for self-evaluation and pessimistic thinking (from 12 years old). - Persistent depressive mood with feelings of insecurity, low self-esteem, anxiety linked to social ineffectiveness, avoidance of social situations (from 10 years old). - Restrictive eating pattern (from 11 years old). - Intrusive thoughts concerning the fear of not being noticed by peers, daily mood swings, anhedonia, apathy, fatigue, and difficulty concentrating. Irritability and impulsivity, leading to self-cutting without specific triggers or suicidal ideation (from 12 years old). CGAS (53)Clinician rating:55/100 Moderate functioning impairments in more than one area Clinician rating:55/100 Moderate functioning impairments in more than one area WISC- IV, Wechsler Intelligence Scale for Children-Fourth Edition (37); ADOS-2, Autism Diagnostic Observation Schedule 2 (38); CSS, calibrated severity score; ADI-R, Autism Diagnostic Interview-Revised (39); SRS-2, Social Responsiveness Scale, second edition (40); ABAS II, The Adaptive Behavior Assessment System Second Edition version (41); CBCL/ 6-18, Child Behavior Checklist7 6-18 (42, 43); PSI, Parenting Stress Index (44); ABC, Aberrant behavior checklist (45); MASC-2, Multidimensional Anxiety Scale for Children-Second Edition (46); CDI-2, Children's Depression Inventory 2 (47); SDSC, Sleep Disturbances Scale for Children (48); SSP-2, Short Sensory Profile -2 (49); YSR, Youth Self-Report (43); BUT, Body Uneasiness Test (50); EDI-3, Eating Disorder Inventory III (51); K-SADS-PL, Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children Present-Lifetime version DSM-5 (52); CGAS, Children’s Global Assessment Scale (53). Table of neuropsychological and psychopathological evaluations. WISC- IV, Wechsler Intelligence Scale for Children-Fourth Edition (37); ADOS-2, Autism Diagnostic Observation Schedule 2 (38); CSS, calibrated severity score; ADI-R, Autism Diagnostic Interview-Revised (39); SRS-2, Social Responsiveness Scale, second edition (40); ABAS II, The Adaptive Behavior Assessment System Second Edition version (41); CBCL/ 6-18, Child Behavior Checklist7 6-18 (42, 43); PSI, Parenting Stress Index (44); ABC, Aberrant behavior checklist (45); MASC-2, Multidimensional Anxiety Scale for Children-Second Edition (46); CDI-2, Children's Depression Inventory 2 (47); SDSC, Sleep Disturbances Scale for Children (48); SSP-2, Short Sensory Profile -2 (49); YSR, Youth Self-Report (43); BUT, Body Uneasiness Test (50); EDI-3, Eating Disorder Inventory III (51); K-SADS-PL, Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children Present-Lifetime version DSM-5 (52); CGAS, Children’s Global Assessment Scale (53). In September 2022, L. attended the ASD Outpatient Unit of the Child and Adolescent Psychiatry Unit, Bambino Gesù Children’s Hospital, IRCSS for further evaluations ( Table 1 ). Based on clinical observation and neuropsychological assessment, the diagnosis of ASD was confirmed in co-occurrence with ARFID and unspecified depressive disorder without any genetic condition associated. Arrangements for both individual CBT and group psychotherapy sessions were reaffirmed to provide a comprehensive and supportive therapeutic plan. Neuropsychological and psychopathological assessment In June 2022, a psychopathological assessment including the Kiddie Schedule for Affective Disorders and Schizophrenia (52) was conducted, alongside parent-report questionnaires, including the Child Behavior Checklist (42), the Children’s Depression Inventory 2 (47), and the Multidimensional Anxiety Scale for Children-Second Edition (46) to detect potential behavioral and emotional co-occurrences. Finally, the Parenting Stress Index (44) was also proposed to her parents. In September 2022, the previous evaluation was expanded to include an investigation of cognitive abilities, using the Wechsler Intelligence Scale for Children-Fourth Edition (37), and Autistic traits through the Autism Diagnostic Observation Schedule-2/module 3 (38), as well as the Autism Diagnostic Interview-Revised (39). Table 1 provides a detailed overview of neuropsychological and psychopathological evaluations conducted in June and September 2022. Genetic analysis In September 2022, L. underwent genetic tests such as Chromosomal Microarray Analysis, FMR1 gene analysis, and karyotype, which did not display any variations. Therapeutic intervention, follow-up, and outcomes Due to the worsening of her symptomatology with persistent irritability, easy impulsivity, restlessness, emotional dysregulation and notable social withdrawal, the need for drug therapy with a new generation antipsychotic was discussed with the family. In October 2022, aripiprazole (2.5 mg/day) was administered and combined with the previous psychological interventions. At the follow-up in December 2022, no improvements were noted and a booster therapy was chosen, increasing the aripiprazole dosage to 3.75 mg/day. At the follow-up in March 2023, L. showed a persistent lack of peer interaction at school, despite some participation in group activities. Her parents reported enhancements in communicative intentionality, mainly with adults. Although daily nutrition has been regulated, selective food intake based on limited taste preferences persisted. Parents reported that individual CBT began in January 2023, accompanied by participation in group therapy but with limited engagement. Despite good compliance with drug therapy, L. expressed concerns about experiencing drowsiness as a side effect. Of note, L. exhibited a greater inclination toward dialogue with clinicians, displaying an increased willingness to answer questions and engage in future planning. L. expressed experiencing anxiety during school performances and the fear of being judged by others. Additionally, she kept on encountering ongoing difficulties falling asleep. Through clinical interviews, we substantiated the presence of a depressive mood with impulsive behavior. Hence, the daily dosage of aripiprazole was increased to 5 mg/day. At the follow-up in January 2024, L. appeared clear-minded, oriented, and well groomed. L. showed less social withdrawal with greater openness to dialogue, actively engaging with clinicians. However, challenges remained in understanding her own emotions and in finding closure on certain topics directly affecting her. Her mood was stable. Pharmacological and psychotherapy plans were reaffirmed without changes. Figure 1 illustrates the timeline of L.’s evaluation history. Timeline summarizing the symptomatology and assessment history of L. Discussion The aim of this paper is to point the evolutionary trajectory of Autistic characteristics in the case of a late diagnosis, showing how delays in the diagnostic process may exacerbate Autistic traits and foster the onset of psychiatric co-occurrences over time (55–57). The advancement of well-being is a fundamental right for all individuals, even in the presence of a pathological condition such as neurodevelopmental disorders (NDDs). To enhance the adaptive functioning and quality of life for individuals with NDDs, a multidisciplinary approach to care is mandatory, addressing both the primary pathology and any co-occurrences and aiming to foster timing diagnosis as they are associated with better outcomes, timely interventions, and reduced burden of the condition and co-occurrences (58, 59). However, timing evaluations are not always performed. Indeed, underdiagnosed states often rise to clinicians’ attention during adolescence, when social demands on individuals gradually increase, exacerbating underlying discomfort by either amplifying an already present but less apparent symptomatology. Possibly the adolescence stage would also uphold the development of additional co-occurring symptoms, which may or not be specific to further and peculiar psychopathological conditions. There is a linear relation between the age of the diagnosis of ASD and mental health co-occurrences, with children diagnosed around 11 years showing the strongest association with other mental health issues (60). This may result from delayed evidence-based treatments and insufficient comprehensive care, potentially hindering the development of adequate coping skills and social support (60, 61). Additionally, the late diagnosis of ASD is more common for females without a learning disability (11). This scenario is linked with the “camouflage hypothesis” (62) for which the attitude of masking Autistic traits, within the presence of internalizing problems, such as depressive and eating disorders, are more common in the phenotype of Autistic females than in males (63, 64). However, research on Autistic females is still scarce (65), generating challenges for a good clinical practice assessment and intervention. The described case exemplifies this background. Firstly, L. received a late diagnosis of ASD at age 10, potentially delaying appropriate therapeutic interventions and the identification of co-occurring conditions. Mood and feeding co-occurrences may have emerged due to the late diagnosis of ASD; the lack of support in presence of Autistic characteristics could have led to elevated stress levels and worsened overall functioning, negatively affecting her well-being. As a result, L. has done a multi-psychopathological pathway. Of note, given her good cognitive abilities it’s possible that L.’s could have tried to mask her Autistic characteristics using camouflage, a common phenomenon in Autistic females (66). If camouflaging could have helped L. in managing everyday challenges, the same tendency might have structured the Autistic traits into multiple co-occurrences with an overtime worsening. Even though strong cognitive skills may provide a greater set of resources for undergoing CBT therapy, potentially leading to more positive effects on psychopathology outcomes (67). Perhaps, in this case, good cognitive abilities may allow for a greater insight capacity with high awareness of one’s own difficulties, leading to a sense of inadequacy and continuous attempts at camouflaging. As seen, L. first developed a transient form of ARFID, with severe weight loss, and then a clear unspecified depressive disorder with Non-Suicidal Self-Injury probably linked to her difficulties in peer relation. It is crucial to pay attention to depressive states in co-occurrence with ASD. Females with strong cognitive skills not only tend to remain frequently undiagnosed but also to manifest increased mood co-occurrences and a higher risk of self-injury (11). The lack of coping strategies in individuals with a similar manifestation of the Spectrum condition may exacerbate social withdrawal. Hence, we decided to tailor an integrated treatment plan for L., combining CBT, psychoeducation and pharmacological intervention. Specifically, therapeutic prescriptions indicated CBT for facing mood (68–73) and feeding (12, 13, 72, 73) co-occurrences. To address L.’s mood difficulties, it was recommended to focus directly on her emotional processes in a proactive and solution-oriented manner. The goal was to improve her self-regulation, enhance her sense of personal efficacy, strengthen her problem-solving abilities, and cultivate a sense of enjoyment and mastery (69). In addition, to manage L.’s food selectivity, an intervention was recommended to help the Autistic girl develop personalized CBT strategies, including self-monitoring, gradual reintroduction of feared foods, and identifying triggers to overcome feeding difficulties (73, 74). Aiming at embracing a person-centered approach, the therapeutic plan also included psychoeducational sessions which emphasized prioritizing and valuing L’s experiences, needs, preferences, passions, pursuits, and desires of the Autistic individual (14, 75, 76). The pharmacological plan was based on the current literature evidence underlining risperidone and aripiprazole as elective drugs for ASD with psychiatric co-occurrences, behavioral problems and RRBs (77, 78). Indeed, aripiprazole, approved by the U.S. Food and Drug Administration for children and adolescents aged from 6 to 17 years to address irritability associated with Autistic traits, may provide an effective short-term pharmacological option for managing specific behavioral co-occurrences (79, 80). Although the best practice intervention for NDDs, such as ASD, would be CBT (81), evaluating the introduction of a pharmacological plan is also crucial. An integrated approach combining pharmacological and psychotherapeutic interventions may be more effective than using either intervention alone, particularly in cases with co-occurrences (82, 83). For instance, the treatment plan of Autistic characteristics with mood co-occurrences should combine non-medical interventions, like CBT, and pharmacological treatments. Similarly, in the case of ARFID co-occurrence with ASD, integrating drugs such as antidepressants, antipsychotics, and stimulants with CBT is recommended. However, evidence remains limited, especially for Autistic adolescents and adults and other psychiatric co-occurrences (83). Concerning ASD and ARFID co-occurrence, there is a gap in the literature exploring their interrelation, leading to a scarcity of solid data. Hence, epidemiological studies, a focus on the manifestation of co-occurrences, and treatment trials should be promoted. As both conditions tend to show an atypical sensory processing as a prevalent feeding feature, it may be particularly challenging for clinicians carrying a differential diagnosis. Available tools are not tailored for it, generating difficulties during the assessment. The Childhood Autism Rating Scale, 2nd Edition (84) and the Short Sensory Profile-2 (49) may allow for a differential investigation of sensory aspects providing an initial support to healthcare workers. For instance, in the aforementioned case, the Short Sensory Profile-2 (49) supported the clinical diagnostic process confirming a clear and distinct FED not attributable to ASD sensitivity. The measure is tailored to catch the peculiar sensory processing pattern of individuals, explaining how information are processed and their behavioral correlates (49). As L.’s sensory profile encompasses the range of “like most people”, it confirms that her food selectivity was not related to the Autistic characteristics but to a clear feeding issue. Hence, the diagnosis of ARFID was timely appropriate to correctly manage her feeding condition. Given the potential overlaps between ASD and ARFID, the decision for a more in-depth investigation into the Spectrum condition was carefully made. This approach also allowed for targeted interventions aimed at preventing future psychiatric co-occurrences. Of note, L.’s case could be read through the lens of the neurodevelopmental continuum paradigm, suggesting ASD and other psychiatric disorders may be understood as part of a pathological continuum pathway (85). This theory holds particular significance for Autistic individuals with low support needs and females with peculiar camouflaging tendencies (86). As it may have happened with L., the ongoing effort to mask the Autistic traits and related issues could result in the development of new co-occurrences connected to a profound distress inherent in camouflaging. The case of L. underscores the importance of implementing research on the manifestation of ASD with a specific focus on adolescence, a developmental stage characterized by an intrinsic vulnerability regardless the presence of an NDD. Further, as the guidelines for ASD of the National Institute for Health and Care Excellence exhort (87), L.’s case highlights the importance of tailored and integrated therapeutic plans based on both pharmacological treatment and psychotherapy. Gold standard diagnostic process and treatment plan should be personalized and run with a holistic perspective that acknowledges the interconnection of psychiatric disorders. The above-mentioned case emphasizes the need for longitudinal research with adequately sized samples to identify evolving patterns of co-occurring symptomatology in a preventive perspective with the aims of implementing a lifespan support and preventing confirmed psychiatric co-occurrences. The peculiar features of the described symptomatic evolution and the comprehensive assessment seem to be points of strength of the current report. However, the main limitations are the paucity of follow-up evaluations over time and of comprehensive information about L.’s early developmental history. Monitoring any potential shifts in L.’s Autistic traits and psychiatric co-occurrences is essential to sustain tailored interventions suited to age-related symptoms. Hence, a longitudinal approach is essential to comprehensively understand the symptomatology pattern of this specific case. Finally, we would like to support and embrace the hypothesis of a delayed diagnosis of ASD as a “fertile ground” for psychiatric co-occurrences, highlighting the decisive importance of assuming a prospective view throughout conditions rather than categorizing them into clear distinguished categories. It is also fundamental to restate that any assessment and treatment plan should be tailored to the manifestation of Autistic traits in relation to age. More studies are required for better understanding the clinical features and the optimal treatment combination for the spectrum condition in presence of psychiatric co-occurrences, especially in Autistic females without learning difficulties.